<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01117948</url>
  </required_header>
  <id_info>
    <org_study_id>CR081101/CO14950</org_study_id>
    <nct_id>NCT01117948</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.</brief_title>
  <official_title>A Multicentre Double-blind, Placebo-controlled, Randomised, Parallel-group Study to Evaluate the Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JSW Lifesciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JSW Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study title: A multicentre double-blind, placebo-controlled, randomised, parallel-group study
      to evaluate the safety and efficacy of Lornoxicam in patients with mild to moderate probable
      Alzheimer's Disease.

      Study phase: II

      Indication: Alzheimer´s Disease

      Investigational product, dose schedule and route of administration: Lornoxicam (8 mg) tablets
      to be taken orally two times daily (BID) for a period of 6 months.

      Reference product, dose, schedule and route of administration: Placebo (8 mg) tablets to be
      taken orally two times daily (BID) for a period of 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study title: A multicentre double-blind, placebo-controlled, randomised, parallel-group study
      to evaluate the safety and efficacy of Lornoxicam in patients with mild to moderate probable
      Alzheimer's Disease.

      Study phase: II

      Indication: Alzheimer´s Disease

      Study objectives: Primary:

      To evaluate the efficacy of Lornoxicam (8 mg, BID) administered for 6 months versus matched
      placebo based on the following end-point:

      • Cognitive performance - ADAS-cog+

      Secondary:

      To evaluate the efficacy of Lornoxicam (8 mg, BID) administered for 6 months versus matched
      placebo based on the following end-point:

        -  Activities of daily living - ADCS-ADL

        -  Behavioral / psychiatric symptoms - NPI

      To evaluate the safety of Lornoxicam (8 mg, BID) administered for 6 months versus matched
      placebo.

      • Overall incidence of adverse events.

      Exploratory:

      In a subgroup of 50 patients MRI analyses will be performed. In a subgroup of 50 patients
      exploratory data on the production of amyloid biological markers - blood plasma concentration
      of Aß1-38, Aß1-40 and Aß1-42 will be collected.

      An optional 6 month open-label phase will be available.

      Subject population, diagnosis and main criteria for inclusion: Male and female patients with
      mild to moderate probable Alzheimer's Disease according to NINCDS-ADRDA criteria

        -  Age 50 - 85 years inclusive

        -  MMSE 18-26 inclusive

        -  No history of treatment with Acetylcholine-esterase inhibitors or 4 weeks wash out
           period before baseline visit.

        -  No history of treatment with Memantine or 4 weeks wash out period before baseline visit.

      Duration of treatment: 6 month double-blind phase 6 month open-label phase (optional)

      Total number of subjects: A total of 220 patients will be recruited to the study from
      approximately 20 centers in a treatment ratio of 1:1 (8 mg BID, 110 : placebo, 110). This
      reflects the minimum number of patients required and also allows for a drop out rate of
      approximately 20%. Additional subjects may be recruited based on interim analysis.

      Number of study centres: Approximately 20; multinational Europe

      Number of visits: Doubble-Blind Phase: 5 visits (including screening); Open-Label Phase: 3
      visits

      Investigational product, dose schedule and route of administration: Lornoxicam (8 mg) tablets
      to be taken orally two times daily (BID) for a period of 6 months.

      Reference product, dose, schedule and route of administration: Placebo (8 mg) tablets to be
      taken orally two times daily (BID) for a period of 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of Efficacy
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive Performance - ADAS-cog+</measure>
    <time_frame>6 months double blind, 6 months open-label (optional)</time_frame>
    <description>Alzheimer's disease Assessment Scale, Cognitive Subscale (15 item) Higher scores indicate cognitive impairment. All items are assessed by independent rater (psychologists). The score goes from 0 points (no cognitive impairment) to 95 points (maximum impairment in all 15 items).
Primary Outcome Measure is the change from baseline ADAS-cog+ score to the score after 26 weeks (end of double blind).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activities of Daily Living - ADCS-ADL; Behavioral/Psychiatric Symptoms - NPI</measure>
    <time_frame>6 months double-blind, 6 months open label (optional)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Alzheimer´s Disease</condition>
  <arm_group>
    <arm_group_label>Lornoxicam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lornoxicam</intervention_name>
    <description>Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.</description>
    <arm_group_label>Lornoxicam</arm_group_label>
    <other_name>Xefo</other_name>
    <other_name>Telos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women (non-childbearing potential) with a diagnosis of Alzheimer's Disease
             according to the NINCDS-ADRDA clinical criteria.

          2. Mild to moderate stage of Alzheimer's disease according to MMSE 18-26 inclusive.

          3. Modified Hachinski Ischemic Scale equal to or below 4.

          4. Geriatric Depression Scale below or equal 7.

          5. If anticholinesterasic treatment had been prescribed, the patient must undergo a 4
             week wash out period before the baseline visit (visit 1).

          6. If Memantine treatment had been prescribed, the patient must undergo a 4 week wash out
             period before the baseline visit (visit 1).

        Exclusion criteria:

        1. Clinical, laboratory or neuroimaging findings consistent with:

          -  other primary degenerative dementia, (dementia with Lewy bodies, frontotemporal
             dementia, Huntington's disease, Jacob-Creutzfeld Disease, Down's syndrome, etc.)

          -  other neurodegenerative condition (Parkinson's Disease, amyotrophic lateral sclerosis,
             etc.)

          -  cerebrovascular Disease (major infarct, one strategic or multiple lacunar infarcts,
             extensive white matter lesions &gt; one quarter of the total white matter)

          -  other central nervous system diseases (severe head trauma, tumors, subdural haematoma
             or other space occupying processes, etc.)

          -  seizure disorder

          -  other infectious, metabolic or systemic diseases affecting central nervous system
             (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency confirmed
             by current analyses not older than 1 month, serum electrolytes out of normal range,
             juvenile onset diabetes mellitus, etc.) 2. A current DSM-IV diagnosis of active major
             depression, schizophrenia or bipolar disorder.

             3. Chronic daily drug intake for a time period of ≥ 14 days or expected for ≥ 14 days:
             &quot;

          -  antidepressants, benzodiazepines, neuroleptics, major sedatives or other
             anti-inflammatory drugs including acetylic salicylic acid defined

          -  antiepileptics

          -  anticholinergics

          -  nootropics (including Ginkgo)

          -  centrally active anti-hypertensive drugs (clonidine, alpha-methyl dopa, guanidine,
             guanfacine,)

          -  opioid containing analgesics

          -  anti-inflammatory agents, cortico-steroids or immunosuppressants

          -  Cimetidin as gastroprotective drug 4. Severe thrombocytopenia defined as platelet
             counts &lt;100.000 per mm3. 5. Coagulation disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Sterner, M.Sc.</last_name>
    <role>Study Director</role>
    <affiliation>JSW-Life Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reinhold Schmidt, MD</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Michael Rainer, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <removed_countries>
    <country>Austria</country>
  </removed_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2010</study_first_submitted>
  <study_first_submitted_qc>May 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2010</study_first_posted>
  <results_first_submitted>May 21, 2012</results_first_submitted>
  <results_first_submitted_qc>October 30, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 29, 2012</results_first_posted>
  <last_update_submitted>February 1, 2013</last_update_submitted>
  <last_update_submitted_qc>February 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lornoxicam</mesh_term>
    <mesh_term>Piroxicam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient in: 09 Nov 2009 Last patient out: 30 Apr 2011 Patients were recruited in Clinics and Outpatient Clinics</recruitment_details>
      <pre_assignment_details>Patients were excluded if they did not meet all inclusion/exclusion criteria or if the caregiver was not giving consent to participation in the trial</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lornoxicam</title>
          <description>Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double Blind</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Open Label</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lornoxicam</title>
          <description>Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="111"/>
            <count group_id="B2" value="108"/>
            <count group_id="B3" value="219"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.5" spread="6.75"/>
                    <measurement group_id="B2" value="73.6" spread="8.11"/>
                    <measurement group_id="B3" value="74.1" spread="7.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cognitive Performance - ADAS-cog+</title>
        <description>Alzheimer's disease Assessment Scale, Cognitive Subscale (15 item) Higher scores indicate cognitive impairment. All items are assessed by independent rater (psychologists). The score goes from 0 points (no cognitive impairment) to 95 points (maximum impairment in all 15 items).
Primary Outcome Measure is the change from baseline ADAS-cog+ score to the score after 26 weeks (end of double blind).</description>
        <time_frame>6 months double blind, 6 months open-label (optional)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lornoxicam</title>
            <description>Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Performance - ADAS-cog+</title>
          <description>Alzheimer's disease Assessment Scale, Cognitive Subscale (15 item) Higher scores indicate cognitive impairment. All items are assessed by independent rater (psychologists). The score goes from 0 points (no cognitive impairment) to 95 points (maximum impairment in all 15 items).
Primary Outcome Measure is the change from baseline ADAS-cog+ score to the score after 26 weeks (end of double blind).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="6.75"/>
                    <measurement group_id="O2" value="-0.89" spread="7.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Activities of Daily Living - ADCS-ADL; Behavioral/Psychiatric Symptoms - NPI</title>
        <time_frame>6 months double-blind, 6 months open label (optional)</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lornoxicam</title>
          <description>Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Myocard infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute ulcus ventriculi</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer with Bulb Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Gastric and duodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Intestinal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Ulcus duodeni perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>External abscess on the neck</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Vertebral algic syndrom, Coxarthrosis - worsenig</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Organic disorder with delusions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgery of lumbar spine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Local ischemy in right cerebellum hemisphera</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>JSW-Lifesciences</organization>
      <phone>0043316 258111 ext 310</phone>
      <email>office@jsw-lifesciences.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

